Lava Medtech Acquisition Stock EBITDA
LVACUDelisted Stock | USD 10.40 0.00 0.00% |
Lava Medtech Acquisition fundamentals help investors to digest information that contributes to Lava Medtech's financial success or failures. It also enables traders to predict the movement of Lava Stock. The fundamental analysis module provides a way to measure Lava Medtech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lava Medtech stock.
Lava |
Lava Medtech Acquisition Company EBITDA Analysis
Lava Medtech's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Lava Medtech EBITDA | (6.22 M) |
Most of Lava Medtech's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lava Medtech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Lava Medtech Acquisition reported earnings before interest,tax, depreciation and amortization of (6.22 Million). This is 100.01% lower than that of the Financial Services sector and significantly lower than that of the Shell Companies industry. The ebitda for all United States stocks is 100.16% higher than that of the company.
Lava EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lava Medtech's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lava Medtech could also be used in its relative valuation, which is a method of valuing Lava Medtech by comparing valuation metrics of similar companies.Lava Medtech is currently under evaluation in ebitda category among its peers.
Lava Fundamentals
Return On Asset | -0.0081 | |||
Shares Owned By Institutions | 10.18 % | |||
Number Of Shares Shorted | 105 | |||
EBITDA | (6.22 M) | |||
Net Income | 4.5 M | |||
Cash And Equivalents | 1.15 M | |||
Cash Per Share | 0.08 X | |||
Total Debt | 92.81 K | |||
Debt To Equity | 4.92 % | |||
Current Ratio | 18.29 X | |||
Book Value Per Share | (0.21) X | |||
Cash Flow From Operations | (658.82 K) | |||
Short Ratio | 1.88 X | |||
Total Asset | 120.67 M | |||
Retained Earnings | (3.01 M) | |||
Working Capital | (3.39 M) | |||
Z Score | -0.24 | |||
Net Asset | 120.67 M |
About Lava Medtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lava Medtech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lava Medtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lava Medtech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Lava Stock
If you are still planning to invest in Lava Medtech Acquisition check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lava Medtech's history and understand the potential risks before investing.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |